25 XP   0   0   10

Takeda Pharmaceutical Co Ltd ADR
Buy, Hold or Sell?

Let's analyse Takeda together

PenkeI guess you are interested in Takeda Pharmaceutical Co Ltd ADR. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Takeda Pharmaceutical Co Ltd ADR. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Takeda Pharmaceutical Co Ltd ADR

I send you an email if I find something interesting about Takeda Pharmaceutical Co Ltd ADR.

Quick analysis of Takeda (30 sec.)










What can you expect buying and holding a share of Takeda? (30 sec.)

How much money do you get?

How much money do you get?
$0.60
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
$13.97
Expected worth in 1 year
$15.14
How sure are you?
67.5%

+ What do you gain per year?

Total Gains per Share
$1.77
Return On Investment
13.2%

For what price can you sell your share?

Current Price per Share
$13.38
Expected price per share
$12.23 - $14.57
How sure are you?
50%

1. Valuation of Takeda (5 min.)




Live pricePrice per Share (EOD)

$13.38

Intrinsic Value Per Share

$-5.11 - $10.90

Total Value Per Share

$8.85 - $24.87

2. Growth of Takeda (5 min.)




Is Takeda growing?

Current yearPrevious yearGrowGrow %
How rich?$43.8b$40.4b$3.5b8.1%

How much money is Takeda making?

Current yearPrevious yearGrowGrow %
Making money$289.6m$446m-$156.4m-54.0%
Net Profit Margin4.2%6.6%--

How much money comes from the company's main activities?

3. Financial Health of Takeda (5 min.)




What can you expect buying and holding a share of Takeda? (5 min.)

Welcome investor! Takeda's management wants to use your money to grow the business. In return you get a share of Takeda.

What can you expect buying and holding a share of Takeda?

First you should know what it really means to hold a share of Takeda. And how you can make/lose money.

Speculation

The Price per Share of Takeda is $13.38. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Takeda.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Takeda, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $13.97. Based on the TTM, the Book Value Change Per Share is $0.29 per quarter. Based on the YOY, the Book Value Change Per Share is $0.44 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.15 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Takeda.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.221.6%0.090.7%0.141.1%0.110.8%0.070.5%
Usd Book Value Change Per Share-0.68-5.1%0.292.2%0.443.3%0.493.6%0.221.7%
Usd Dividend Per Share0.292.1%0.151.1%0.141.1%0.151.1%0.110.8%
Usd Total Gains Per Share-0.39-2.9%0.443.3%0.584.3%0.634.7%0.332.5%
Usd Price Per Share14.27-15.48-14.23-16.41-19.78-
Price to Earnings Ratio16.29-15.63--23.70-92.85-437.90-
Price-to-Total Gains Ratio-36.22-15.99-6.09-119.14-78.39-
Price to Book Ratio1.02-1.11-1.11-1.46-3.34-
Price-to-Total Gains Ratio-36.22-15.99-6.09-119.14-78.39-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share13.38
Number of shares74
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.150.15
Usd Book Value Change Per Share0.290.49
Usd Total Gains Per Share0.440.63
Gains per Quarter (74 shares)32.7546.86
Gains per Year (74 shares)131.00187.44
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1448712143144177
28817425287288364
3133260383130432551
4177347514173576738
5221434645217720925
62655217762608651112
731060790730310091299
8354694103834711531486
9398781116939012971673
10442868130043314411860

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%10.02.00.083.3%16.04.00.080.0%31.09.00.077.5%44.09.00.083.0%
Book Value Change Per Share3.01.00.075.0%10.02.00.083.3%12.08.00.060.0%23.017.00.057.5%33.019.01.062.3%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%53.00.00.0100.0%
Total Gains per Share3.01.00.075.0%10.02.00.083.3%15.05.00.075.0%27.013.00.067.5%39.014.00.073.6%

Fundamentals of Takeda

About Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Fundamental data was last updated by Penke on 2024-04-05 02:52:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Takeda Pharmaceutical Co Ltd ADR.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Takeda earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Takeda to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 9.5% means that $0.10 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Takeda Pharmaceutical Co Ltd ADR:

  • The MRQ is 9.5%. The company is making a profit. +1
  • The TTM is 4.2%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ9.5%TTM4.2%+5.4%
TTM4.2%YOY6.6%-2.5%
TTM4.2%5Y5.5%-1.3%
5Y5.5%10Y4.8%+0.7%
1.1.2. Return on Assets

Shows how efficient Takeda is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Takeda to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.7% Return on Assets means that Takeda generated $0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Takeda Pharmaceutical Co Ltd ADR:

  • The MRQ is 0.7%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.3%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.7%TTM0.3%+0.4%
TTM0.3%YOY0.5%-0.2%
TTM0.3%5Y0.4%-0.1%
5Y0.4%10Y0.4%0.0%
1.1.3. Return on Equity

Shows how efficient Takeda is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Takeda to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.6% Return on Equity means Takeda generated $0.02 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Takeda Pharmaceutical Co Ltd ADR:

  • The MRQ is 1.6%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 0.7%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.6%TTM0.7%+0.9%
TTM0.7%YOY1.1%-0.4%
TTM0.7%5Y0.9%-0.2%
5Y0.9%10Y0.9%0.0%

1.2. Operating Efficiency of Takeda Pharmaceutical Co Ltd ADR.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Takeda is operating .

  • Measures how much profit Takeda makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Takeda to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 11.5% means the company generated $0.12  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Takeda Pharmaceutical Co Ltd ADR:

  • The MRQ is 11.5%. The company is operating less efficient.
  • The TTM is 10.0%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ11.5%TTM10.0%+1.5%
TTM10.0%YOY10.5%-0.5%
TTM10.0%5Y10.4%-0.4%
5Y10.4%10Y9.0%+1.4%
1.2.2. Operating Ratio

Measures how efficient Takeda is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.94 means that the operating costs are $0.94 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Takeda Pharmaceutical Co Ltd ADR:

  • The MRQ is 0.940. The company is less efficient in keeping operating costs low.
  • The TTM is 0.934. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.940TTM0.934+0.006
TTM0.934YOY0.902+0.032
TTM0.9345Y0.917+0.017
5Y0.91710Y0.924-0.008

1.3. Liquidity of Takeda Pharmaceutical Co Ltd ADR.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Takeda is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.06 means the company has $1.06 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Takeda Pharmaceutical Co Ltd ADR:

  • The MRQ is 1.064. The company is just able to pay all its short-term debts.
  • The TTM is 1.015. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.064TTM1.015+0.050
TTM1.015YOY1.173-0.159
TTM1.0155Y1.251-0.236
5Y1.25110Y1.464-0.214
1.3.2. Quick Ratio

Measures if Takeda is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Takeda to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.48 means the company can pay off $0.48 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Takeda Pharmaceutical Co Ltd ADR:

  • The MRQ is 0.477. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.490. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.477TTM0.490-0.013
TTM0.490YOY0.707-0.216
TTM0.4905Y0.715-0.224
5Y0.71510Y1.102-0.388

1.4. Solvency of Takeda Pharmaceutical Co Ltd ADR.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Takeda assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Takeda to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.53 means that Takeda assets are financed with 52.6% credit (debt) and the remaining percentage (100% - 52.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Takeda Pharmaceutical Co Ltd ADR:

  • The MRQ is 0.526. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.532. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.526TTM0.532-0.006
TTM0.532YOY0.551-0.019
TTM0.5325Y0.585-0.053
5Y0.58510Y0.542+0.043
1.4.2. Debt to Equity Ratio

Measures if Takeda is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Takeda to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 111.0% means that company has $1.11 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Takeda Pharmaceutical Co Ltd ADR:

  • The MRQ is 1.110. The company is able to pay all its debts with equity. +1
  • The TTM is 1.137. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.110TTM1.137-0.027
TTM1.137YOY1.226-0.090
TTM1.1375Y1.430-0.294
5Y1.43010Y1.234+0.196

2. Market Valuation of Takeda Pharmaceutical Co Ltd ADR

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Takeda generates.

  • Above 15 is considered overpriced but always compare Takeda to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 16.29 means the investor is paying $16.29 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Takeda Pharmaceutical Co Ltd ADR:

  • The EOD is 15.274. Based on the earnings, the company is fair priced.
  • The MRQ is 16.290. Based on the earnings, the company is fair priced.
  • The TTM is 15.627. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD15.274MRQ16.290-1.016
MRQ16.290TTM15.627+0.663
TTM15.627YOY-23.698+39.326
TTM15.6275Y92.848-77.220
5Y92.84810Y437.899-345.052
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Takeda Pharmaceutical Co Ltd ADR:

  • The EOD is 23.292. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 24.841. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 3.846. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD23.292MRQ24.841-1.549
MRQ24.841TTM3.846+20.996
TTM3.846YOY-25.133+28.979
TTM3.8465Y6.112-2.266
5Y6.11210Y57.010-50.897
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Takeda is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Takeda Pharmaceutical Co Ltd ADR:

  • The EOD is 0.958. Based on the equity, the company is cheap. +2
  • The MRQ is 1.022. Based on the equity, the company is underpriced. +1
  • The TTM is 1.106. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.958MRQ1.022-0.064
MRQ1.022TTM1.106-0.085
TTM1.106YOY1.111-0.005
TTM1.1065Y1.465-0.358
5Y1.46510Y3.342-1.877
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Takeda Pharmaceutical Co Ltd ADR.

3.1. Institutions holding Takeda Pharmaceutical Co Ltd ADR

Institutions are holding 2.664% of the shares of Takeda Pharmaceutical Co Ltd ADR.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Capital Research Global Investors0.45570.0502142978055034463.6497
2023-12-31Goldman Sachs Group Inc0.27420.0118605124375531277.4321
2023-12-31Mondrian Investment Partners Ltd0.26031.842381673934085678100.0971
2023-12-31Millennium Management LLC0.20690.04016492911273053272.5746
2023-12-31Morgan Stanley - Brokerage Accounts0.15450.00614847535-385746-7.371
2023-12-31Renaissance Technologies Corp0.1060.07353327400965002.9868
2023-12-31Brandes Investment Partners & Co0.08450.5744265126584922947.1261
2023-12-31Macquarie Group Ltd0.0780.04032445942-1313556-34.9397
2023-12-31FMR Inc0.06940.00242178390-414960-16.0009
2023-12-31Arrowstreet Capital Limited Partnership0.06080.02861908221-565689-22.8662
2023-12-31Polygon Management Ltd0.06076.5413190366200
2023-12-31Northern Trust Corp0.05780.00471814159-376111-17.1719
2023-12-31BlackRock Inc0.05650.00061771942-522527-22.7733
2023-12-31Managed Asset Portfolios, LLC0.0563.80381758081216651.2477
2023-12-31Envestnet Asset Management Inc0.05060.009415888131232572345.9939
2023-12-31Causeway Capital Management LLC0.04290.488913456451013368.144
2023-12-31Van Eck Associates Corporation0.04220.03441323916456163.5685
2023-12-31Y.D. More Investments Ltd0.043.43981254591-126959-9.1896
2023-12-31OLD MISSION CAPITAL LLC0.03320.272510415269739351440.9241
2023-12-31Bank of America Corp0.02660.0012834313-1365965-62.0815
Total 2.216817.265569558634+9324308+13.4%

3.2. Funds holding Takeda Pharmaceutical Co Ltd ADR

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Capital Group American Mutual Comp0.45090.22141475274947043.6235
2023-12-31American Funds American Mutual A0.45090.22141475274947043.6235
2024-02-29VanEck Pharmaceutical ETF0.04624.1515145032700
2023-12-31MAP Global Equity Composite0.02222.5267695946-617-0.0886
2023-12-31MAP Global Balanced Composite0.01672.329652440967981.3133
2023-12-31MAP Global Equity Ex-Options Composite0.01412.59443997-1293-0.2904
2023-12-31SGI Global Equity I0.012.814131354400
2023-12-31Manning & Napier Disciplined Value - Unr0.00910.7155285095-13725-4.5931
2023-12-31Causeway Simulated Intl Val ADR Model0.00861.45426915500
2023-12-31Russell Personalized Core Equity SMA0.00830.3361258954160796.6203
2023-12-31PMC Diversified Equity0.00730.4261229071-37601-14.1001
2023-12-31Virtus KAR Equity Income A0.0072.50772196507073447.4993
2023-09-30Dimensional SMA Global ex US Large Core0.00690.33792179672179670
2024-02-29Avantis International Equity ETF0.00690.079421510800
2024-02-29ActivePassive International Equity ETF0.00591.047318642819601.0625
2024-02-29Russell Personalized 70/30 Core Alloc0.00520.23511625931625930
2023-12-31Capital Group American Mutual Trust U00.00480.219915027887426.1765
2023-12-31Virtus Rampart Enhanced Core Equity A0.00462.48611454214842449.9232
2023-12-31Catalyst/MAP Global Equity A0.00462.72121430001500011.7188
2024-02-29abrdn World Healthcare0.00330.261510507300
Total 1.093527.679734311070+1484469+4.3%

3.3. Insider Transactions

Insiders are holding 0.004% of the shares of Takeda Pharmaceutical Co Ltd ADR.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-01-24Pharmaceutical Co Ltd TakedaSELL37037038.1

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Takeda Pharmaceutical Co Ltd ADR compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.6800.293-332%0.437-256%0.487-240%0.222-406%
Book Value Per Share--13.96714.0290%12.879+8%11.553+21%8.014+74%
Current Ratio--1.0641.015+5%1.173-9%1.251-15%1.464-27%
Debt To Asset Ratio--0.5260.532-1%0.551-4%0.585-10%0.542-3%
Debt To Equity Ratio--1.1101.137-2%1.226-10%1.430-22%1.234-10%
Dividend Per Share--0.2860.149+92%0.145+98%0.146+96%0.110+160%
Eps--0.2190.092+137%0.142+54%0.110+100%0.066+231%
Free Cash Flow Per Share--0.144-0.067+147%0.423-66%0.269-47%0.167-14%
Free Cash Flow To Equity Per Share---0.059-0.224+280%-0.066+12%-0.003-94%0.079-174%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--10.899--------
Intrinsic Value_10Y_min---5.114--------
Intrinsic Value_1Y_max--1.099--------
Intrinsic Value_1Y_min--0.469--------
Intrinsic Value_3Y_max--3.297--------
Intrinsic Value_3Y_min--0.568--------
Intrinsic Value_5Y_max--5.489--------
Intrinsic Value_5Y_min---0.256--------
Market Cap41984163901.440-7%44776832501.76048581451240.960-8%44697851494.080+0%51485405750.208-13%62062299371.232-28%
Net Profit Margin--0.0950.042+129%0.066+44%0.055+73%0.048+98%
Operating Margin--0.1150.100+15%0.105+10%0.104+11%0.090+28%
Operating Ratio--0.9400.934+1%0.902+4%0.917+3%0.924+2%
Pb Ratio0.958-7%1.0221.106-8%1.111-8%1.465-30%3.342-69%
Pe Ratio15.274-7%16.29015.627+4%-23.698+245%92.848-82%437.899-96%
Price Per Share13.380-7%14.27015.483-8%14.233+0%16.406-13%19.778-28%
Price To Free Cash Flow Ratio23.292-7%24.8413.846+546%-25.133+201%6.112+306%57.010-56%
Price To Total Gains Ratio-33.965+6%-36.22515.992-327%6.090-695%119.138-130%78.391-146%
Quick Ratio--0.4770.490-3%0.707-32%0.715-33%1.102-57%
Return On Assets--0.0070.003+138%0.005+51%0.004+93%0.004+76%
Return On Equity--0.0160.007+135%0.011+46%0.009+72%0.009+67%
Total Gains Per Share---0.3940.443-189%0.582-168%0.633-162%0.332-219%
Usd Book Value--43826945500.00044021204500.0000%40447701125.000+8%36257321100.000+21%25150139462.500+74%
Usd Book Value Change Per Share---0.6800.293-332%0.437-256%0.487-240%0.222-406%
Usd Book Value Per Share--13.96714.0290%12.879+8%11.553+21%8.014+74%
Usd Dividend Per Share--0.2860.149+92%0.145+98%0.146+96%0.110+160%
Usd Eps--0.2190.092+137%0.142+54%0.110+100%0.066+231%
Usd Free Cash Flow--450625500.000-209681875.000+147%1328624375.000-66%845430625.000-47%523056462.500-14%
Usd Free Cash Flow Per Share--0.144-0.067+147%0.423-66%0.269-47%0.167-14%
Usd Free Cash Flow To Equity Per Share---0.059-0.224+280%-0.066+12%-0.003-94%0.079-174%
Usd Market Cap41984163901.440-7%44776832501.76048581451240.960-8%44697851494.080+0%51485405750.208-13%62062299371.232-28%
Usd Price Per Share13.380-7%14.27015.483-8%14.233+0%16.406-13%19.778-28%
Usd Profit--687180000.000289605875.000+137%446075500.000+54%330696925.000+108%229748675.000+199%
Usd Revenue--7222709000.0006774704625.000+7%6409994500.000+13%5855066100.000+23%4369331525.000+65%
Usd Total Gains Per Share---0.3940.443-189%0.582-168%0.633-162%0.332-219%
 EOD+5 -3MRQTTM+20 -15YOY+21 -145Y+18 -1710Y+19 -16

4.2. Fundamental Score

Let's check the fundamental score of Takeda Pharmaceutical Co Ltd ADR based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1515.274
Price to Book Ratio (EOD)Between0-10.958
Net Profit Margin (MRQ)Greater than00.095
Operating Margin (MRQ)Greater than00.115
Quick Ratio (MRQ)Greater than10.477
Current Ratio (MRQ)Greater than11.064
Debt to Asset Ratio (MRQ)Less than10.526
Debt to Equity Ratio (MRQ)Less than11.110
Return on Equity (MRQ)Greater than0.150.016
Return on Assets (MRQ)Greater than0.050.007
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Takeda Pharmaceutical Co Ltd ADR based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.304
Ma 20Greater thanMa 5013.518
Ma 50Greater thanMa 10013.953
Ma 100Greater thanMa 20013.997
OpenGreater thanClose13.370
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Other Assets  72,790,6262,790,63241,1912,831,823-2,831,81013-20-7



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in JPY. All numbers in thousands.

Summary
Total Assets14,222,947,000
Total Liabilities7,480,340,000
Total Stockholder Equity6,741,934,000
 As reported
Total Liabilities 7,480,340,000
Total Stockholder Equity+ 6,741,934,000
Total Assets = 14,222,947,000

Assets

Total Assets14,222,947,000
Total Current Assets2,428,830,000
Long-term Assets11,794,118,000
Total Current Assets
Cash And Cash Equivalents 288,359,000
Short-term Investments 29,045,000
Net Receivables 743,079,000
Inventory 1,169,640,000
Other Current Assets 179,394,000
Total Current Assets  (as reported)2,428,830,000
Total Current Assets  (calculated)2,409,517,000
+/- 19,313,000
Long-term Assets
Property Plant Equipment 1,841,499,000
Goodwill 5,111,287,000
Long Term Investments 372,918,000
Intangible Assets 4,097,022,000
Long-term Assets Other 54,703,000
Long-term Assets  (as reported)11,794,118,000
Long-term Assets  (calculated)11,477,429,000
+/- 316,689,000

Liabilities & Shareholders' Equity

Total Current Liabilities2,282,168,000
Long-term Liabilities5,198,172,000
Total Stockholder Equity6,741,934,000
Total Current Liabilities
Short-term Debt 370,292,000
Short Long Term Debt 370,292,000
Accounts payable 483,666,000
Other Current Liabilities 833,297,000
Total Current Liabilities  (as reported)2,282,168,000
Total Current Liabilities  (calculated)2,057,547,000
+/- 224,621,000
Long-term Liabilities
Long term Debt 4,293,872,000
Long-term Liabilities Other 614,599,000
Long-term Liabilities  (as reported)5,198,172,000
Long-term Liabilities  (calculated)4,908,471,000
+/- 289,701,000
Total Stockholder Equity
Common Stock1,676,543,000
Retained Earnings 1,396,838,000
Accumulated Other Comprehensive Income 1,989,669,000
Other Stockholders Equity 1,678,884,000
Total Stockholder Equity (as reported)6,741,934,000
Total Stockholder Equity (calculated)6,741,934,000
+/-0
Other
Capital Stock1,676,543,000
Cash and Short Term Investments 317,404,000
Common Stock Shares Outstanding 1,585,118
Current Deferred Revenue594,913,000
Liabilities and Stockholders Equity 14,222,947,000
Net Debt 4,375,805,000
Net Invested Capital 11,406,098,000
Net Working Capital 146,662,000
Short Long Term Debt Total 4,664,164,000



Balance Sheet

Currency in JPY. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-30
> Total Assets 
2,554,650,000
2,554,650,000
2,760,188,000
2,760,188,000
2,739,933,000
2,753,315,000
2,823,274,000
2,684,347,000
2,708,669,000
2,680,068,000
2,786,402,000
2,713,566,000
3,499,283,000
3,421,383,000
3,577,030,000
3,467,951,000
3,482,163,000
3,783,727,000
3,955,599,000
3,933,711,000
4,253,216,000
4,425,786,000
4,569,144,000
4,437,328,000
4,571,807,000
4,653,372,000
4,296,192,000
4,320,850,000
4,213,829,000
4,189,879,000
3,824,085,000
3,817,012,000
3,801,817,000
4,142,032,000
4,355,782,000
4,345,922,000
4,375,955,000
4,410,558,000
4,106,463,000
4,159,577,000
4,274,839,000
5,767,223,000
13,872,322,000
13,550,424,000
12,880,141,000
13,031,494,000
12,821,094,000
12,613,852,000
12,414,747,000
12,286,137,000
12,912,293,000
12,657,234,000
12,560,273,000
12,698,519,000
13,178,018,000
14,065,426,000
14,588,847,000
13,504,705,000
13,957,750,000
14,792,738,000
14,871,889,000
14,222,947,000
14,222,947,00014,871,889,00014,792,738,00013,957,750,00013,504,705,00014,588,847,00014,065,426,00013,178,018,00012,698,519,00012,560,273,00012,657,234,00012,912,293,00012,286,137,00012,414,747,00012,613,852,00012,821,094,00013,031,494,00012,880,141,00013,550,424,00013,872,322,0005,767,223,0004,274,839,0004,159,577,0004,106,463,0004,410,558,0004,375,955,0004,345,922,0004,355,782,0004,142,032,0003,801,817,0003,817,012,0003,824,085,0004,189,879,0004,213,829,0004,320,850,0004,296,192,0004,653,372,0004,571,807,0004,437,328,0004,569,144,0004,425,786,0004,253,216,0003,933,711,0003,955,599,0003,783,727,0003,482,163,0003,467,951,0003,577,030,0003,421,383,0003,499,283,0002,713,566,0002,786,402,0002,680,068,0002,708,669,0002,684,347,0002,823,274,0002,753,315,0002,739,933,0002,760,188,0002,760,188,0002,554,650,0002,554,650,000
   > Total Current Assets 
0
1,307,591,000
1,475,584,000
0
1,506,032,000
1,496,885,000
1,572,874,000
1,466,181,000
1,501,063,000
1,482,261,000
1,586,252,000
1,543,455,000
1,274,499,000
1,240,921,000
1,278,996,000
1,197,194,000
1,241,767,000
1,331,251,000
1,455,081,000
1,382,289,000
1,712,950,000
1,784,297,000
1,592,536,000
1,531,358,000
1,633,648,000
1,703,791,000
1,520,072,000
1,471,481,000
1,480,221,000
1,549,712,000
1,373,787,000
1,473,528,000
1,484,302,000
1,656,260,000
1,260,662,000
1,270,818,000
1,221,996,000
1,265,978,000
1,078,808,000
1,043,548,000
1,107,943,000
2,670,072,000
3,050,658,000
2,932,156,000
2,374,440,000
2,520,325,000
2,469,432,000
2,474,763,000
2,585,136,000
2,616,598,000
2,712,893,000
2,476,458,000
2,456,353,000
2,477,893,000
2,593,642,000
2,549,515,000
2,745,616,000
2,595,946,000
2,397,956,000
2,472,017,000
2,462,066,000
2,428,830,000
2,428,830,0002,462,066,0002,472,017,0002,397,956,0002,595,946,0002,745,616,0002,549,515,0002,593,642,0002,477,893,0002,456,353,0002,476,458,0002,712,893,0002,616,598,0002,585,136,0002,474,763,0002,469,432,0002,520,325,0002,374,440,0002,932,156,0003,050,658,0002,670,072,0001,107,943,0001,043,548,0001,078,808,0001,265,978,0001,221,996,0001,270,818,0001,260,662,0001,656,260,0001,484,302,0001,473,528,0001,373,787,0001,549,712,0001,480,221,0001,471,481,0001,520,072,0001,703,791,0001,633,648,0001,531,358,0001,592,536,0001,784,297,0001,712,950,0001,382,289,0001,455,081,0001,331,251,0001,241,767,0001,197,194,0001,278,996,0001,240,921,0001,274,499,0001,543,455,0001,586,252,0001,482,261,0001,501,063,0001,466,181,0001,572,874,0001,496,885,0001,506,032,00001,475,584,0001,307,591,0000
       Cash And Cash Equivalents 
0
222,565,000
229,533,000
0
260,721,000
275,116,000
266,538,000
229,765,000
221,982,000
193,250,000
217,897,000
191,266,000
248,551,000
192,691,000
454,247,000
205,395,000
212,538,000
262,241,000
289,613,000
266,883,000
352,579,000
441,329,000
666,048,000
622,915,000
681,453,000
781,507,000
652,148,000
576,404,000
608,281,000
560,952,000
451,426,000
581,670,000
619,144,000
559,166,000
319,455,000
432,302,000
430,895,000
440,253,000
294,522,000
231,480,000
317,080,000
297,873,000
702,093,000
593,745,000
543,517,000
568,279,000
637,614,000
589,787,000
630,868,000
617,635,000
966,222,000
654,920,000
607,881,000
724,341,000
849,695,000
645,991,000
798,137,000
685,141,000
533,530,000
316,380,000
318,051,000
288,359,000
288,359,000318,051,000316,380,000533,530,000685,141,000798,137,000645,991,000849,695,000724,341,000607,881,000654,920,000966,222,000617,635,000630,868,000589,787,000637,614,000568,279,000543,517,000593,745,000702,093,000297,873,000317,080,000231,480,000294,522,000440,253,000430,895,000432,302,000319,455,000559,166,000619,144,000581,670,000451,426,000560,952,000608,281,000576,404,000652,148,000781,507,000681,453,000622,915,000666,048,000441,329,000352,579,000266,883,000289,613,000262,241,000212,538,000205,395,000454,247,000192,691,000248,551,000191,266,000217,897,000193,250,000221,982,000229,765,000266,538,000275,116,000260,721,0000229,533,000222,565,0000
       Short-term Investments 
0
384,033,000
529,248,000
0
547,591,000
532,288,000
616,678,000
541,417,000
583,590,000
569,129,000
656,321,000
629,078,000
157,393,000
191,746,000
1,378,000
175,937,000
199,477,000
159,852,000
258,092,000
117,999,000
366,557,000
291,317,000
184,981,000
139,829,000
159,908,000
74,992,000
61,275,000
61,519,000
59,312,000
99,558,000
108,600,000
151,101,000
120,032,000
179,281,000
56,683,000
57,979,000
29,771,000
26,227,000
80,646,000
19,147,000
20,281,000
1,566,330,000
23,276,000
21,342,000
13,916,000
20,144,000
15,822,000
11,138,000
15,314,000
36,664,000
36,598,000
29,930,000
25,742,000
27,555,000
25,305,000
18,543,000
31,932,000
41,467,000
20,174,000
52,229,000
15,756,000
29,045,000
29,045,00015,756,00052,229,00020,174,00041,467,00031,932,00018,543,00025,305,00027,555,00025,742,00029,930,00036,598,00036,664,00015,314,00011,138,00015,822,00020,144,00013,916,00021,342,00023,276,0001,566,330,00020,281,00019,147,00080,646,00026,227,00029,771,00057,979,00056,683,000179,281,000120,032,000151,101,000108,600,00099,558,00059,312,00061,519,00061,275,00074,992,000159,908,000139,829,000184,981,000291,317,000366,557,000117,999,000258,092,000159,852,000199,477,000175,937,0001,378,000191,746,000157,393,000629,078,000656,321,000569,129,000583,590,000541,417,000616,678,000532,288,000547,591,0000529,248,000384,033,0000
       Net Receivables 
0
508,479,000
520,546,000
0
524,893,000
520,167,000
516,885,000
517,738,000
521,392,000
534,665,000
523,904,000
519,681,000
577,050,000
600,290,000
550,504,000
547,435,000
546,586,000
601,186,000
585,681,000
603,744,000
624,371,000
668,755,000
442,664,000
442,085,000
461,779,000
500,221,000
466,829,000
479,830,000
478,365,000
493,734,000
430,571,000
440,418,000
446,199,000
496,864,000
444,778,000
471,163,000
470,857,000
518,685,000
428,792,000
459,715,000
468,919,000
515,791,000
749,119,000
788,629,000
805,737,000
852,128,000
784,921,000
815,271,000
769,806,000
828,942,000
812,714,000
858,957,000
887,295,000
756,117,000
724,377,000
794,092,000
800,536,000
779,872,000
681,693,000
825,481,000
788,066,000
743,079,000
743,079,000788,066,000825,481,000681,693,000779,872,000800,536,000794,092,000724,377,000756,117,000887,295,000858,957,000812,714,000828,942,000769,806,000815,271,000784,921,000852,128,000805,737,000788,629,000749,119,000515,791,000468,919,000459,715,000428,792,000518,685,000470,857,000471,163,000444,778,000496,864,000446,199,000440,418,000430,571,000493,734,000478,365,000479,830,000466,829,000500,221,000461,779,000442,085,000442,664,000668,755,000624,371,000603,744,000585,681,000601,186,000546,586,000547,435,000550,504,000600,290,000577,050,000519,681,000523,904,000534,665,000521,392,000517,738,000516,885,000520,167,000524,893,0000520,546,000508,479,0000
       Other Current Assets 
0
65,343,000
64,599,000
0
36,906,000
30,552,000
35,077,000
41,607,000
38,669,000
49,229,000
51,003,000
63,570,000
50,197,000
46,671,000
77,854,000
64,908,000
74,727,000
83,482,000
92,164,000
156,139,000
130,909,000
130,998,000
43,509,000
56,756,000
51,347,000
62,646,000
63,223,000
75,529,000
58,726,000
61,093,000
64,145,000
56,928,000
59,696,000
71,215,000
75,146,000
72,982,000
55,183,000
55,088,000
57,912,000
69,964,000
68,130,000
64,503,000
109,666,000
108,093,000
104,697,000
116,890,000
114,196,000
108,064,000
111,215,000
115,703,000
122,789,000
133,308,000
131,841,000
138,353,000
141,098,000
163,378,000
155,636,000
154,824,000
160,867,000
179,883,000
178,219,000
179,394,000
179,394,000178,219,000179,883,000160,867,000154,824,000155,636,000163,378,000141,098,000138,353,000131,841,000133,308,000122,789,000115,703,000111,215,000108,064,000114,196,000116,890,000104,697,000108,093,000109,666,00064,503,00068,130,00069,964,00057,912,00055,088,00055,183,00072,982,00075,146,00071,215,00059,696,00056,928,00064,145,00061,093,00058,726,00075,529,00063,223,00062,646,00051,347,00056,756,00043,509,000130,998,000130,909,000156,139,00092,164,00083,482,00074,727,00064,908,00077,854,00046,671,00050,197,00063,570,00051,003,00049,229,00038,669,00041,607,00035,077,00030,552,00036,906,000064,599,00065,343,0000
   > Long-term Assets 
0
1,247,059,000
1,284,604,000
0
1,233,901,000
1,256,430,000
1,250,400,000
1,218,166,000
1,207,606,000
1,197,807,000
1,200,150,000
1,170,111,000
2,224,784,000
2,180,462,000
2,298,034,000
2,270,757,000
2,240,396,000
2,452,475,000
2,500,518,000
2,551,423,000
2,540,266,000
2,641,489,000
2,976,607,000
2,905,971,000
2,938,159,000
2,949,580,000
2,776,118,000
2,849,371,000
2,733,608,000
2,640,167,000
2,450,298,000
2,343,484,000
2,317,516,000
2,485,771,000
3,095,122,000
3,075,106,000
3,153,958,000
3,144,581,000
3,027,655,000
3,116,029,000
3,166,896,000
3,097,151,000
10,821,664,000
10,618,268,000
10,505,701,000
10,511,169,000
10,351,662,000
10,139,089,000
9,829,611,000
9,669,539,000
10,199,400,000
10,180,777,000
10,103,920,000
10,220,627,000
10,584,376,000
11,515,910,000
11,843,231,000
10,908,758,000
11,559,794,000
12,320,721,000
12,409,821,000
11,794,118,000
11,794,118,00012,409,821,00012,320,721,00011,559,794,00010,908,758,00011,843,231,00011,515,910,00010,584,376,00010,220,627,00010,103,920,00010,180,777,00010,199,400,0009,669,539,0009,829,611,00010,139,089,00010,351,662,00010,511,169,00010,505,701,00010,618,268,00010,821,664,0003,097,151,0003,166,896,0003,116,029,0003,027,655,0003,144,581,0003,153,958,0003,075,106,0003,095,122,0002,485,771,0002,317,516,0002,343,484,0002,450,298,0002,640,167,0002,733,608,0002,849,371,0002,776,118,0002,949,580,0002,938,159,0002,905,971,0002,976,607,0002,641,489,0002,540,266,0002,551,423,0002,500,518,0002,452,475,0002,240,396,0002,270,757,0002,298,034,0002,180,462,0002,224,784,0001,170,111,0001,200,150,0001,197,807,0001,207,606,0001,218,166,0001,250,400,0001,256,430,0001,233,901,00001,284,604,0001,247,059,0000
       Property Plant Equipment 
0
251,080,000
258,493,000
0
264,867,000
291,709,000
318,949,000
353,509,000
382,944,000
402,451,000
407,480,000
403,219,000
474,492,000
490,985,000
488,702,000
487,011,000
489,585,000
504,377,000
511,101,000
509,870,000
503,051,000
507,295,000
542,253,000
532,605,000
535,266,000
539,801,000
526,162,000
526,127,000
517,605,000
516,718,000
551,916,000
529,339,000
537,486,000
523,314,000
530,152,000
532,337,000
541,209,000
541,688,000
536,801,000
528,155,000
533,088,000
601,774,000
1,316,531,000
1,481,113,000
1,457,060,000
1,468,842,000
1,386,370,000
1,366,177,000
1,366,950,000
1,363,141,000
1,453,917,000
1,452,172,000
1,459,919,000
1,493,587,000
1,582,800,000
1,705,367,000
1,760,327,000
1,656,416,000
1,691,229,000
1,795,315,000
1,894,136,000
1,841,499,000
1,841,499,0001,894,136,0001,795,315,0001,691,229,0001,656,416,0001,760,327,0001,705,367,0001,582,800,0001,493,587,0001,459,919,0001,452,172,0001,453,917,0001,363,141,0001,366,950,0001,366,177,0001,386,370,0001,468,842,0001,457,060,0001,481,113,0001,316,531,000601,774,000533,088,000528,155,000536,801,000541,688,000541,209,000532,337,000530,152,000523,314,000537,486,000529,339,000551,916,000516,718,000517,605,000526,127,000526,162,000539,801,000535,266,000532,605,000542,253,000507,295,000503,051,000509,870,000511,101,000504,377,000489,585,000487,011,000488,702,000490,985,000474,492,000403,219,000407,480,000402,451,000382,944,000353,509,000318,949,000291,709,000264,867,0000258,493,000251,080,0000
       Goodwill 
0
273,246,000
284,446,000
0
255,717,000
256,252,000
256,117,000
239,998,000
224,195,000
216,831,000
217,123,000
207,555,000
538,683,000
522,061,000
582,257,000
563,797,000
567,982,000
638,613,000
675,353,000
704,030,000
707,466,000
748,706,000
814,671,000
800,496,000
821,515,000
880,981,000
821,911,000
858,819,000
836,339,000
818,741,000
779,316,000
706,672,000
697,261,000
777,344,000
1,022,711,000
1,052,983,000
1,072,962,000
1,078,236,000
1,029,248,000
1,053,998,000
1,085,706,000
1,053,506,000
4,161,403,000
4,064,572,000
4,029,507,000
4,104,150,000
4,012,528,000
3,984,271,000
3,856,147,000
3,824,804,000
4,033,917,000
4,058,935,000
4,078,369,000
4,167,993,000
4,407,749,000
4,813,610,000
4,994,632,000
4,690,949,000
4,790,723,000
5,182,128,000
5,301,017,000
5,111,287,000
5,111,287,0005,301,017,0005,182,128,0004,790,723,0004,690,949,0004,994,632,0004,813,610,0004,407,749,0004,167,993,0004,078,369,0004,058,935,0004,033,917,0003,824,804,0003,856,147,0003,984,271,0004,012,528,0004,104,150,0004,029,507,0004,064,572,0004,161,403,0001,053,506,0001,085,706,0001,053,998,0001,029,248,0001,078,236,0001,072,962,0001,052,983,0001,022,711,000777,344,000697,261,000706,672,000779,316,000818,741,000836,339,000858,819,000821,911,000880,981,000821,515,000800,496,000814,671,000748,706,000707,466,000704,030,000675,353,000638,613,000567,982,000563,797,000582,257,000522,061,000538,683,000207,555,000217,123,000216,831,000224,195,000239,998,000256,117,000256,252,000255,717,0000284,446,000273,246,0000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,297,439
2,874,404
2,985,428
3,747,255
2,581,383
306,899,000
308,937,000
350,578,000
394,532,000
369,455,000
336,638,000
349,602,000
376,051,000
348,350,000
374,659,000
352,091,000
334,812,000
330,133,000
381,607,000
425,766,000
369,469,000
378,857,000
393,529,000
416,364,000
372,918,000
372,918,000416,364,000393,529,000378,857,000369,469,000425,766,000381,607,000330,133,000334,812,000352,091,000374,659,000348,350,000376,051,000349,602,000336,638,000369,455,000394,532,000350,578,000308,937,000306,899,0002,581,3833,747,2552,985,4282,874,4043,297,4390000000000000000000000000000000000000
       Intangible Assets 
0
446,083,000
463,299,000
0
402,395,000
392,226,000
383,778,000
356,423,000
330,788,000
311,752,000
300,304,000
281,762,000
922,807,000
878,956,000
892,703,000
928,705,000
908,250,000
1,015,674,000
1,014,382,000
1,055,288,000
1,054,950,000
1,107,807,000
1,135,597,000
1,098,586,000
1,099,174,000
1,058,229,000
939,381,000
950,985,000
890,036,000
798,335,000
743,128,000
662,001,000
608,537,000
684,861,000
1,065,835,000
1,055,752,000
1,092,637,000
1,073,469,000
1,014,264,000
1,057,985,000
1,067,172,000
1,020,216,000
4,860,368,000
4,580,341,000
4,425,199,000
4,308,394,000
4,171,361,000
4,043,156,000
3,878,257,000
3,756,723,000
3,909,106,000
3,856,432,000
3,783,677,000
3,791,875,000
3,818,544,000
4,145,090,000
4,187,055,000
3,765,757,000
4,269,657,000
4,514,084,000
4,402,421,000
4,097,022,000
4,097,022,0004,402,421,0004,514,084,0004,269,657,0003,765,757,0004,187,055,0004,145,090,0003,818,544,0003,791,875,0003,783,677,0003,856,432,0003,909,106,0003,756,723,0003,878,257,0004,043,156,0004,171,361,0004,308,394,0004,425,199,0004,580,341,0004,860,368,0001,020,216,0001,067,172,0001,057,985,0001,014,264,0001,073,469,0001,092,637,0001,055,752,0001,065,835,000684,861,000608,537,000662,001,000743,128,000798,335,000890,036,000950,985,000939,381,0001,058,229,0001,099,174,0001,098,586,0001,135,597,0001,107,807,0001,054,950,0001,055,288,0001,014,382,0001,015,674,000908,250,000928,705,000892,703,000878,956,000922,807,000281,762,000300,304,000311,752,000330,788,000356,423,000383,778,000392,226,000402,395,0000463,299,000446,083,0000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,000
0
-1,000
0
0
1,000
-1,000
0
1,000
2,000
-2,000
0
0
0
0
-1,000
1,000
-2,000
-2,000
1,000
-1,000
1,349,988
1,305,938
474,207
1,266,712
176,463,000
183,305,000
243,357,000
235,251,000
411,948,000
408,847,000
378,655,000
348,820,000
454,110,000
-1,000
429,864,000
-1,000
1,000
1,000
804,345,000
1,000
429,328,000
435,665,000
2,000
-1,000
-1,0002,000435,665,000429,328,0001,000804,345,0001,0001,000-1,000429,864,000-1,000454,110,000348,820,000378,655,000408,847,000411,948,000235,251,000243,357,000183,305,000176,463,0001,266,712474,2071,305,9381,349,988-1,0001,000-2,000-2,0001,000-1,0000000-2,0002,0001,0000-1,0001,00000-1,00001,00000000000000000000
> Total Liabilities 
0
635,818,000
706,348,000
0
651,112,000
646,572,000
658,529,000
599,371,000
595,184,000
587,535,000
649,746,000
597,159,000
1,454,231,000
1,446,501,000
1,505,164,000
1,517,752,000
1,510,965,000
1,661,314,000
1,732,240,000
1,657,197,000
1,906,048,000
1,972,543,000
2,028,509,000
1,983,330,000
2,040,875,000
2,080,506,000
2,090,016,000
2,089,229,000
2,031,515,000
2,027,508,000
1,812,882,000
1,947,729,000
1,922,774,000
2,097,623,000
2,406,817,000
2,309,139,000
2,270,258,000
2,276,475,000
2,089,054,000
2,093,003,000
2,102,678,000
3,724,645,000
8,708,734,000
8,675,973,000
8,010,457,000
8,155,275,000
8,093,608,000
7,923,088,000
7,748,248,000
7,646,709,000
7,735,116,000
7,418,591,000
7,235,912,000
7,366,696,000
7,494,495,000
7,748,043,000
7,875,358,000
7,328,207,000
7,603,079,000
7,871,069,000
7,800,864,000
7,480,340,000
7,480,340,0007,800,864,0007,871,069,0007,603,079,0007,328,207,0007,875,358,0007,748,043,0007,494,495,0007,366,696,0007,235,912,0007,418,591,0007,735,116,0007,646,709,0007,748,248,0007,923,088,0008,093,608,0008,155,275,0008,010,457,0008,675,973,0008,708,734,0003,724,645,0002,102,678,0002,093,003,0002,089,054,0002,276,475,0002,270,258,0002,309,139,0002,406,817,0002,097,623,0001,922,774,0001,947,729,0001,812,882,0002,027,508,0002,031,515,0002,089,229,0002,090,016,0002,080,506,0002,040,875,0001,983,330,0002,028,509,0001,972,543,0001,906,048,0001,657,197,0001,732,240,0001,661,314,0001,510,965,0001,517,752,0001,505,164,0001,446,501,0001,454,231,000597,159,000649,746,000587,535,000595,184,000599,371,000658,529,000646,572,000651,112,0000706,348,000635,818,0000
   > Total Current Liabilities 
0
409,768,000
472,106,000
0
429,918,000
426,447,000
428,477,000
368,000,000
375,452,000
375,067,000
436,596,000
389,436,000
1,017,201,000
1,027,025,000
751,731,000
726,437,000
488,281,000
572,790,000
613,632,000
543,620,000
546,986,000
581,084,000
802,754,000
740,638,000
779,162,000
837,920,000
1,016,824,000
1,010,949,000
985,980,000
1,011,248,000
857,213,000
822,761,000
808,837,000
957,948,000
1,366,091,000
939,624,000
838,769,000
878,170,000
737,509,000
733,444,000
844,192,000
871,707,000
2,510,931,000
2,006,623,000
1,634,634,000
2,127,365,000
2,175,898,000
2,031,544,000
1,709,661,000
1,804,958,000
1,773,176,000
1,706,782,000
1,918,750,000
1,809,254,000
2,145,730,000
2,166,942,000
2,391,720,000
2,236,809,000
2,481,940,000
2,501,741,000
2,367,617,000
2,282,168,000
2,282,168,0002,367,617,0002,501,741,0002,481,940,0002,236,809,0002,391,720,0002,166,942,0002,145,730,0001,809,254,0001,918,750,0001,706,782,0001,773,176,0001,804,958,0001,709,661,0002,031,544,0002,175,898,0002,127,365,0001,634,634,0002,006,623,0002,510,931,000871,707,000844,192,000733,444,000737,509,000878,170,000838,769,000939,624,0001,366,091,000957,948,000808,837,000822,761,000857,213,0001,011,248,000985,980,0001,010,949,0001,016,824,000837,920,000779,162,000740,638,000802,754,000581,084,000546,986,000543,620,000613,632,000572,790,000488,281,000726,437,000751,731,0001,027,025,0001,017,201,000389,436,000436,596,000375,067,000375,452,000368,000,000428,477,000426,447,000429,918,0000472,106,000409,768,0000
       Short-term Debt 
0
3,699,000
3,214,000
0
3,101,000
3,265,000
3,285,000
3,058,000
2,992,000
3,201,000
1,345,000
1,270,000
571,335,000
541,263,000
244,702,000
241,456,000
1,511,000
1,671,000
1,795,000
1,525,000
1,332,000
1,422,000
155,404,000
153,356,000
165,397,000
181,791,000
99,965,000
99,974,000
99,983,000
99,997,000
228,464,000
214,625,000
211,467,000
235,844,000
545,028,000
203,635,000
139,989,000
140,000,000
18,000
1,185,000
120,913,000
120,743,000
984,946,000
520,665,000
171,391,000
611,701,000
586,817,000
580,732,000
276,616,000
284,474,000
22,153,000
24,272,000
214,886,000
122,936,000
203,993,000
281,897,000
568,228,000
372,019,000
339,600,000
416,860,000
274,841,000
370,292,000
370,292,000274,841,000416,860,000339,600,000372,019,000568,228,000281,897,000203,993,000122,936,000214,886,00024,272,00022,153,000284,474,000276,616,000580,732,000586,817,000611,701,000171,391,000520,665,000984,946,000120,743,000120,913,0001,185,00018,000140,000,000139,989,000203,635,000545,028,000235,844,000211,467,000214,625,000228,464,00099,997,00099,983,00099,974,00099,965,000181,791,000165,397,000153,356,000155,404,0001,422,0001,332,0001,525,0001,795,0001,671,0001,511,000241,456,000244,702,000541,263,000571,335,0001,270,0001,345,0003,201,0002,992,0003,058,0003,285,0003,265,0003,101,00003,214,0003,699,0000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,242,732
0
0
1,061,339
1,101,921
984,946,000
520,665,000
171,391,000
611,701,000
586,817,000
580,732,000
276,616,000
284,474,000
22,153,000
24,272,000
214,886,000
122,936,000
203,993,000
281,897,000
568,228,000
372,019,000
339,600,000
416,860,000
274,841,000
370,292,000
370,292,000274,841,000416,860,000339,600,000372,019,000568,228,000281,897,000203,993,000122,936,000214,886,00024,272,00022,153,000284,474,000276,616,000580,732,000586,817,000611,701,000171,391,000520,665,000984,946,0001,101,9211,061,339001,242,7320000000000000000000000000000000000000
       Accounts payable 
0
75,474,000
238,797,000
0
72,808,000
74,643,000
195,906,000
73,492,000
75,381,000
82,693,000
211,374,000
75,651,000
89,886,000
97,962,000
98,453,000
99,463,000
98,006,000
108,648,000
118,692,000
106,395,000
107,887,000
122,927,000
184,900,000
154,733,000
155,223,000
168,488,000
170,782,000
172,898,000
157,658,000
170,420,000
191,089,000
190,310,000
196,877,000
231,832,000
240,623,000
219,633,000
209,677,000
223,452,000
240,259,000
225,492,000
225,752,000
248,616,000
212,348,000
278,886,000
280,409,000
299,892,000
318,816,000
289,741,000
272,778,000
326,978,000
343,838,000
320,645,000
336,600,000
351,185,000
516,297,000
424,358,000
388,616,000
381,109,000
649,233,000
440,924,000
421,078,000
483,666,000
483,666,000421,078,000440,924,000649,233,000381,109,000388,616,000424,358,000516,297,000351,185,000336,600,000320,645,000343,838,000326,978,000272,778,000289,741,000318,816,000299,892,000280,409,000278,886,000212,348,000248,616,000225,752,000225,492,000240,259,000223,452,000209,677,000219,633,000240,623,000231,832,000196,877,000190,310,000191,089,000170,420,000157,658,000172,898,000170,782,000168,488,000155,223,000154,733,000184,900,000122,927,000107,887,000106,395,000118,692,000108,648,00098,006,00099,463,00098,453,00097,962,00089,886,00075,651,000211,374,00082,693,00075,381,00073,492,000195,906,00074,643,00072,808,0000238,797,00075,474,0000
       Other Current Liabilities 
0
267,834,000
21,409,000
0
230,717,000
251,634,000
16,182,000
219,563,000
200,266,000
214,058,000
14,910,000
225,791,000
247,863,000
281,153,000
164,690,000
297,483,000
278,691,000
296,289,000
51,307,000
348,321,000
330,434,000
366,047,000
284,769,000
257,945,000
250,900,000
283,561,000
286,419,000
255,865,000
237,086,000
266,742,000
279,186,000
255,837,000
234,027,000
282,284,000
374,060,000
292,156,000
260,656,000
282,635,000
296,757,000
315,832,000
291,864,000
303,509,000
686,373,000
725,300,000
578,502,000
629,027,000
682,282,000
556,911,000
557,990,000
595,995,000
790,704,000
750,639,000
764,123,000
728,211,000
1,425,440,000
1,460,687,000
1,434,876,000
1,483,681,000
1,493,107,000
873,428,000
883,823,000
833,297,000
833,297,000883,823,000873,428,0001,493,107,0001,483,681,0001,434,876,0001,460,687,0001,425,440,000728,211,000764,123,000750,639,000790,704,000595,995,000557,990,000556,911,000682,282,000629,027,000578,502,000725,300,000686,373,000303,509,000291,864,000315,832,000296,757,000282,635,000260,656,000292,156,000374,060,000282,284,000234,027,000255,837,000279,186,000266,742,000237,086,000255,865,000286,419,000283,561,000250,900,000257,945,000284,769,000366,047,000330,434,000348,321,00051,307,000296,289,000278,691,000297,483,000164,690,000281,153,000247,863,000225,791,00014,910,000214,058,000200,266,000219,563,00016,182,000251,634,000230,717,000021,409,000267,834,0000
   > Long-term Liabilities 
0
226,050,000
234,242,000
0
221,194,000
220,125,000
230,052,000
231,371,000
219,732,000
212,468,000
213,150,000
207,723,000
437,030,000
419,476,000
753,433,000
791,315,000
1,022,684,000
1,088,524,000
1,118,608,000
1,113,577,000
1,359,062,000
1,391,459,000
1,225,755,000
1,242,692,000
1,261,713,000
1,242,586,000
1,073,192,000
1,078,280,000
1,045,535,000
1,016,260,000
955,669,000
1,124,968,000
1,113,937,000
1,139,675,000
1,040,726,000
1,369,515,000
1,431,489,000
1,398,305,000
1,351,545,000
1,359,559,000
1,258,486,000
2,852,938,000
6,197,803,000
6,669,350,000
6,375,823,000
6,027,910,000
5,917,710,000
5,891,544,000
6,038,587,000
5,841,751,000
5,961,940,000
5,711,809,000
5,317,162,000
5,557,442,000
5,348,765,000
5,581,101,000
5,483,638,000
5,091,398,000
5,121,139,000
5,369,328,000
5,433,247,000
5,198,172,000
5,198,172,0005,433,247,0005,369,328,0005,121,139,0005,091,398,0005,483,638,0005,581,101,0005,348,765,0005,557,442,0005,317,162,0005,711,809,0005,961,940,0005,841,751,0006,038,587,0005,891,544,0005,917,710,0006,027,910,0006,375,823,0006,669,350,0006,197,803,0002,852,938,0001,258,486,0001,359,559,0001,351,545,0001,398,305,0001,431,489,0001,369,515,0001,040,726,0001,139,675,0001,113,937,0001,124,968,000955,669,0001,016,260,0001,045,535,0001,078,280,0001,073,192,0001,242,586,0001,261,713,0001,242,692,0001,225,755,0001,391,459,0001,359,062,0001,113,577,0001,118,608,0001,088,524,0001,022,684,000791,315,000753,433,000419,476,000437,030,000207,723,000213,150,000212,468,000219,732,000231,371,000230,052,000220,125,000221,194,0000234,242,000226,050,0000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,466,574,000
4,613,218,000
4,381,589,000
4,016,473,000
4,231,939,000
4,141,418,000
4,320,357,000
4,168,417,000
3,914,884,000
4,042,741,000
4,330,254,000
4,404,363,000
0
04,404,363,0004,330,254,0004,042,741,0003,914,884,0004,168,417,0004,320,357,0004,141,418,0004,231,939,0004,016,473,0004,381,589,0004,613,218,0004,466,574,0000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,549,226
2,973,502
3,298,372
3,325,565
3,877,691
1,254,532,000
1,123,010,000
1,113,367,000
1,009,445,000
1,082,848,000
991,164,000
930,564,000
879,871,000
831,045,000
1,330,220,000
1,300,689,000
1,325,503,000
1,207,347,000
1,260,744,000
766,877,000
672,972,000
544,129,000
0
454,010,000
0
0454,010,0000544,129,000672,972,000766,877,0001,260,744,0001,207,347,0001,325,503,0001,300,689,0001,330,220,000831,045,000879,871,000930,564,000991,164,0001,082,848,0001,009,445,0001,113,367,0001,123,010,0001,254,532,0003,877,6913,325,5653,298,3722,973,5023,549,2260000000000000000000000000000000000000
> Total Stockholder Equity
0
1,876,912,000
2,011,451,000
0
2,045,724,000
2,063,656,000
2,121,338,000
2,040,797,000
2,068,812,000
2,048,157,000
2,091,924,000
2,071,305,000
1,987,709,000
1,917,169,000
2,012,345,000
1,891,613,000
1,912,728,000
2,062,155,000
2,159,939,000
2,212,073,000
2,282,374,000
2,382,903,000
2,470,739,000
2,388,581,000
2,463,880,000
2,503,479,000
2,137,047,000
2,165,238,000
2,119,439,000
2,098,862,000
1,948,692,000
1,808,683,000
1,819,158,000
1,981,581,000
1,894,261,000
2,014,570,000
2,085,734,000
2,113,885,000
1,997,424,000
2,043,500,000
2,168,358,000
2,038,682,000
5,159,582,000
4,870,365,000
4,865,714,000
4,872,072,000
4,723,483,000
4,686,763,000
4,662,402,000
4,635,353,000
5,173,037,000
5,238,258,000
5,323,935,000
5,331,330,000
5,683,019,000
6,316,832,000
6,712,929,000
6,175,978,000
6,354,122,000
6,921,052,000
7,070,352,000
6,741,934,000
6,741,934,0007,070,352,0006,921,052,0006,354,122,0006,175,978,0006,712,929,0006,316,832,0005,683,019,0005,331,330,0005,323,935,0005,238,258,0005,173,037,0004,635,353,0004,662,402,0004,686,763,0004,723,483,0004,872,072,0004,865,714,0004,870,365,0005,159,582,0002,038,682,0002,168,358,0002,043,500,0001,997,424,0002,113,885,0002,085,734,0002,014,570,0001,894,261,0001,981,581,0001,819,158,0001,808,683,0001,948,692,0002,098,862,0002,119,439,0002,165,238,0002,137,047,0002,503,479,0002,463,880,0002,388,581,0002,470,739,0002,382,903,0002,282,374,0002,212,073,0002,159,939,0002,062,155,0001,912,728,0001,891,613,0002,012,345,0001,917,169,0001,987,709,0002,071,305,0002,091,924,0002,048,157,0002,068,812,0002,040,797,0002,121,338,0002,063,656,0002,045,724,00002,011,451,0001,876,912,0000
   Common Stock
0
63,541,000
63,541,000
0
63,541,000
63,541,000
63,541,000
63,541,000
63,541,000
63,541,000
63,541,000
63,541,000
63,541,000
63,541,000
63,541,000
63,541,000
63,541,000
0
0
0
0
0
103,428,000
114,916,000
117,866,000
120,421,000
123,619,000
121,237,000
125,376,000
129,373,000
133,595,000
126,236,000
130,761,000
134,680,000
140,175,000
130,103,000
135,498,000
141,068,000
168,654,000
155,477,000
159,719,000
165,040,000
1,643,585,000
1,668,092,000
1,668,092,000
1,668,092,000
1,668,123,000
1,668,145,000
1,668,145,000
1,668,145,000
1,668,145,000
1,669,125,000
1,676,263,000
1,676,263,000
1,676,263,000
1,676,277,000
1,676,330,000
1,676,334,000
1,676,345,000
1,676,411,000
1,676,503,000
1,676,543,000
1,676,543,0001,676,503,0001,676,411,0001,676,345,0001,676,334,0001,676,330,0001,676,277,0001,676,263,0001,676,263,0001,676,263,0001,669,125,0001,668,145,0001,668,145,0001,668,145,0001,668,145,0001,668,123,0001,668,092,0001,668,092,0001,668,092,0001,643,585,000165,040,000159,719,000155,477,000168,654,000141,068,000135,498,000130,103,000140,175,000134,680,000130,761,000126,236,000133,595,000129,373,000125,376,000121,237,000123,619,000120,421,000117,866,000114,916,000103,428,0000000063,541,00063,541,00063,541,00063,541,00063,541,00063,541,00063,541,00063,541,00063,541,00063,541,00063,541,00063,541,00063,541,000063,541,00063,541,0000
   Retained Earnings Total Equity00000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-526,284,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-4,795,000
709,000
0
0
-638,421,000
0
0
0
-697,754,000
87,807,000
0
41,551,000
0
0
0
0
0
0
1,911,167,000
1,380,201,000
1,508,119,000
0
2,287,968,000
1,989,669,000
1,989,669,0002,287,968,00001,508,119,0001,380,201,0001,911,167,00000000041,551,000087,807,000-697,754,000000-638,421,00000709,000-4,795,00000000000000000000000000-526,284,00000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,661,474,000
1,668,872,000
1,678,656,000
1,688,424,000
1,682,504,000
1,686,493,000
1,697,562,000
1,708,873,000
1,707,336,000
1,695,544,000
1,712,036,000
1,728,830,000
1,741,937,000
1,711,109,000
0
01,711,109,0001,741,937,0001,728,830,0001,712,036,0001,695,544,0001,707,336,0001,708,873,0001,697,562,0001,686,493,0001,682,504,0001,688,424,0001,678,656,0001,668,872,0001,661,474,00000000000000000000000000000000000000000000000000
   Treasury Stock00000000-91,013,000-41,037,000-42,344,000-59,552,000-59,567,000-59,565,000-60,717,00000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
-255,583,000
-64,341,000
0
-147,062,000
-127,593,000
-108,506,000
-182,107,000
-234,192,000
-255,075,000
-243,684,000
-268,791,000
-412,461,000
-436,890,000
221,013,000
-442,511,000
-453,545,000
-188,641,000
-83,174,000
10,942,000
45,661,000
170,897,000
466,004,000
420,224,000
466,852,000
558,086,000
412,102,000
482,011,000
400,909,000
387,925,000
291,970,000
132,470,000
114,768,000
299,906,000
242,269,000
298,139,000
335,871,000
362,976,000
276,258,000
294,017,000
360,545,000
258,738,000
1,946,632,000
1,797,247,000
1,720,033,000
1,825,533,000
2,383,142,000
1,600,757,000
1,657,192,000
1,619,089,000
1,994,986,000
2,065,322,000
2,096,522,000
2,188,141,000
2,527,040,000
3,180,791,000
1,595,232,000
1,611,723,000
1,628,512,000
3,754,544,000
1,659,863,000
1,678,884,000
1,678,884,0001,659,863,0003,754,544,0001,628,512,0001,611,723,0001,595,232,0003,180,791,0002,527,040,0002,188,141,0002,096,522,0002,065,322,0001,994,986,0001,619,089,0001,657,192,0001,600,757,0002,383,142,0001,825,533,0001,720,033,0001,797,247,0001,946,632,000258,738,000360,545,000294,017,000276,258,000362,976,000335,871,000298,139,000242,269,000299,906,000114,768,000132,470,000291,970,000387,925,000400,909,000482,011,000412,102,000558,086,000466,852,000420,224,000466,004,000170,897,00045,661,00010,942,000-83,174,000-188,641,000-453,545,000-442,511,000221,013,000-436,890,000-412,461,000-268,791,000-243,684,000-255,075,000-234,192,000-182,107,000-108,506,000-127,593,000-147,062,0000-64,341,000-255,583,0000



Balance Sheet

Currency in JPY. All numbers in thousands.




Cash Flow

Currency in JPY. All numbers in thousands.




Income Statement

Currency in JPY. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue4,027,478,000
Cost of Revenue-1,244,072,000
Gross Profit2,783,406,0002,783,406,000
 
Operating Income (+$)
Gross Profit2,783,406,000
Operating Expense-2,292,900,000
Operating Income490,505,000490,506,000
 
Operating Expense (+$)
Research Development633,325,000
Selling General Administrative997,309,000
Selling And Marketing Expenses0
Operating Expense2,292,900,0001,630,634,000
 
Net Interest Income (+$)
Interest Income62,913,000
Interest Expense-169,698,000
Other Finance Cost-0
Net Interest Income-106,785,000
 
Pretax Income (+$)
Operating Income490,505,000
Net Interest Income-106,785,000
Other Non-Operating Income Expenses0
Income Before Tax (EBT)375,090,000605,920,000
EBIT - interestExpense = 320,807,000
375,069,000
486,715,000
Interest Expense169,698,000
Earnings Before Interest and Taxes (EBIT)490,505,000544,788,000
Earnings Before Interest and Taxes (EBITDA)1,209,188,000
 
After tax Income (+$)
Income Before Tax375,090,000
Tax Provision-58,052,000
Net Income From Continuing Ops317,038,000317,038,000
Net Income317,017,000
Net Income Applicable To Common Shares317,017,000
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses3,536,972,000
Total Other Income/Expenses Net-115,415,000106,785,000
 

Technical Analysis of Takeda
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Takeda. The general trend of Takeda is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Takeda's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Takeda Pharmaceutical Co Ltd ADR.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 14.37 < 14.56 < 14.57.

The bearish price targets are: 12.91 > 12.82 > 12.23.

Tweet this
Takeda Pharmaceutical Co Ltd ADR Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Takeda Pharmaceutical Co Ltd ADR. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Takeda Pharmaceutical Co Ltd ADR Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Takeda Pharmaceutical Co Ltd ADR. The current macd is -0.20300418.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Takeda price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Takeda. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Takeda price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Takeda Pharmaceutical Co Ltd ADR Daily Moving Average Convergence/Divergence (MACD) ChartTakeda Pharmaceutical Co Ltd ADR Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Takeda Pharmaceutical Co Ltd ADR. The current adx is 25.76.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Takeda shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Takeda Pharmaceutical Co Ltd ADR Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Takeda Pharmaceutical Co Ltd ADR. The current sar is 13.11.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Takeda Pharmaceutical Co Ltd ADR Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Takeda Pharmaceutical Co Ltd ADR. The current rsi is 41.30. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Takeda Pharmaceutical Co Ltd ADR Daily Relative Strength Index (RSI) ChartTakeda Pharmaceutical Co Ltd ADR Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Takeda Pharmaceutical Co Ltd ADR. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Takeda price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Takeda Pharmaceutical Co Ltd ADR Daily Stochastic Oscillator ChartTakeda Pharmaceutical Co Ltd ADR Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Takeda Pharmaceutical Co Ltd ADR. The current cci is -52.48455325.

Takeda Pharmaceutical Co Ltd ADR Daily Commodity Channel Index (CCI) ChartTakeda Pharmaceutical Co Ltd ADR Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Takeda Pharmaceutical Co Ltd ADR. The current cmo is -11.8916998.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Takeda Pharmaceutical Co Ltd ADR Daily Chande Momentum Oscillator (CMO) ChartTakeda Pharmaceutical Co Ltd ADR Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Takeda Pharmaceutical Co Ltd ADR. The current willr is -59.39849624.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Takeda is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Takeda Pharmaceutical Co Ltd ADR Daily Williams %R ChartTakeda Pharmaceutical Co Ltd ADR Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Takeda Pharmaceutical Co Ltd ADR.

Takeda Pharmaceutical Co Ltd ADR Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Takeda Pharmaceutical Co Ltd ADR. The current atr is 0.16360115.

Takeda Pharmaceutical Co Ltd ADR Daily Average True Range (ATR) ChartTakeda Pharmaceutical Co Ltd ADR Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Takeda Pharmaceutical Co Ltd ADR. The current obv is -15,639,138.

Takeda Pharmaceutical Co Ltd ADR Daily On-Balance Volume (OBV) ChartTakeda Pharmaceutical Co Ltd ADR Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Takeda Pharmaceutical Co Ltd ADR. The current mfi is 57.13.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Takeda Pharmaceutical Co Ltd ADR Daily Money Flow Index (MFI) ChartTakeda Pharmaceutical Co Ltd ADR Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Takeda Pharmaceutical Co Ltd ADR.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.

6.3. Candlestick Patterns

Takeda Pharmaceutical Co Ltd ADR Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Takeda Pharmaceutical Co Ltd ADR based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.304
Ma 20Greater thanMa 5013.518
Ma 50Greater thanMa 10013.953
Ma 100Greater thanMa 20013.997
OpenGreater thanClose13.370
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Takeda with someone you think should read this too:
  • Are you bullish or bearish on Takeda? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Takeda? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Takeda Pharmaceutical Co Ltd ADR

I send you an email if I find something interesting about Takeda Pharmaceutical Co Ltd ADR.


Comments

How you think about this?

Leave a comment

Stay informed about Takeda Pharmaceutical Co Ltd ADR.

Receive notifications about Takeda Pharmaceutical Co Ltd ADR in your mailbox!